Pure Bioscience Depreciation & Amortization Growth & History (PURE)
Pure Bioscience's depreciation and amortization was $2,000 for fiscal 2025.
View full Pure Bioscience company overviewPure Bioscience annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-07-31 | $2,000 | −$146,000 | −98.65% |
| 2024 | 2024-07-31 | $148,000 | $31,000 | +26.50% |
| 2023 | 2023-07-31 | $117,000 | −$96,000 | −45.07% |
| 2022 | 2022-07-31 | $213,000 | $41,000 | +23.84% |
| 2021 | 2021-07-31 | $172,000 | −$20,000 | −10.42% |
| 2020 | 2020-07-31 | $192,000 | −$49,000 | −20.33% |
| 2019 | 2019-07-31 | $241,000 | −$44,000 | −15.44% |
| 2018 | 2018-07-31 | $285,000 | $9,000 | +3.26% |
| 2017 | 2017-07-31 | $276,000 | $57,000 | +26.03% |
| 2016 | 2016-07-31 | $219,000 | $13,000 | +6.31% |
| 2015 | 2015-07-31 | $206,000 | −$42,000 | −16.94% |
| 2014 | 2014-07-31 | $248,000 | −$63,000 | −20.26% |
| 2013 | 2013-07-31 | $311,000 | −$74,000 | −19.22% |
| 2012 | 2012-08-14 | $385,000 | −$86,000 | −18.26% |
| 2011 | 2011-07-31 | $471,000 | — | — |
Pure Bioscience quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-04-30 | $1,000 | $0 | 0.00% |
| Q2 2026 | 2026-01-31 | $1,000 | $0 | 0.00% |
| Q1 2026 | 2025-10-31 | $1,000 | — | — |
| Q3 2025 | 2025-04-30 | $1,000 | −$35,000 | −97.22% |
| Q2 2025 | 2025-01-31 | $1,000 | −$36,000 | −97.30% |
| Q3 2024 | 2024-04-30 | $36,000 | $1,000 | +2.86% |
| Q2 2024 | 2024-01-31 | $37,000 | $0 | 0.00% |
| Q1 2024 | 2023-10-31 | $37,000 | $7,000 | +23.33% |
| Q3 2023 | 2023-04-30 | $35,000 | −$17,000 | −32.69% |
| Q2 2023 | 2023-01-31 | $37,000 | −$15,000 | −28.85% |
| Q1 2023 | 2022-10-31 | $30,000 | −$28,000 | −48.28% |
| Q3 2022 | 2022-04-30 | $52,000 | $9,000 | +20.93% |
| Q2 2022 | 2022-01-31 | $52,000 | $7,000 | +15.56% |
| Q1 2022 | 2021-10-31 | $58,000 | $13,000 | +28.89% |
| Q3 2021 | 2021-04-30 | $43,000 | −$2,000 | −4.44% |
| Q2 2021 | 2021-01-31 | $45,000 | −$3,000 | −6.25% |
| Q1 2021 | 2020-10-31 | $45,000 | −$7,000 | −13.46% |
| Q3 2020 | 2020-04-30 | $45,000 | −$3,000 | −6.25% |
| Q2 2020 | 2020-01-31 | $48,000 | −$24,000 | −33.33% |
| Q1 2020 | 2019-10-31 | $52,000 | −$19,000 | −26.76% |
| Q3 2019 | 2019-04-30 | $48,000 | −$84,000 | −63.64% |
| Q2 2019 | 2019-01-31 | $72,000 | $62,000 | +620.00% |
| Q1 2019 | 2018-10-31 | $71,000 | $0 | 0.00% |
| Q3 2018 | 2018-04-30 | $132,000 | $62,000 | +88.57% |
| Q2 2018 | 2018-01-31 | $10,000 | −$59,000 | −85.51% |
| Q1 2018 | 2017-10-31 | $71,000 | $6,000 | +9.23% |
| Q3 2017 | 2017-04-30 | $70,000 | $19,000 | +37.25% |
| Q2 2017 | 2017-01-31 | $69,000 | $17,000 | +32.69% |
| Q1 2017 | 2016-10-31 | $65,000 | $14,000 | +27.45% |
| Q3 2016 | 2016-04-30 | $51,000 | $0 | 0.00% |
| Q2 2016 | 2016-01-31 | $52,000 | $0 | 0.00% |
| Q1 2016 | 2015-10-31 | $51,000 | $0 | 0.00% |
| Q3 2015 | 2015-04-30 | $51,000 | −$5,000 | −8.93% |
| Q2 2015 | 2015-01-31 | $52,000 | −$15,000 | −22.39% |
| Q1 2015 | 2014-10-31 | $51,000 | −$22,000 | −30.14% |
| Q3 2014 | 2014-04-30 | $56,000 | −$22,000 | −28.21% |
| Q2 2014 | 2014-01-31 | $67,000 | −$18,000 | −21.18% |
| Q1 2014 | 2013-10-31 | $73,000 | $0 | 0.00% |
| Q3 2013 | 2013-04-30 | $78,000 | −$5,000 | −6.02% |
| Q2 2013 | 2013-01-31 | $85,000 | −$14,000 | −14.14% |
| Q1 2013 | 2012-10-31 | $73,000 | −$44,000 | −37.61% |
| Q3 2012 | 2012-04-30 | $83,000 | −$35,000 | −29.66% |
| Q2 2012 | 2012-01-31 | $99,000 | −$17,000 | −14.66% |
| Q1 2012 | 2011-10-31 | $117,000 | −$1,000 | −0.85% |
| Q3 2011 | 2011-04-30 | $118,000 | — | — |
| Q2 2011 | 2011-01-31 | $116,000 | — | — |
| Q1 2011 | 2010-10-31 | $118,000 | — | — |
Pure Bioscience depreciation and amortization trends
Over the last five fiscal years, Pure Bioscience's depreciation and amortization decreased from $192,000 to $2,000, a change of −$190,000. The latest reported quarter, Q3 2026, shows $1,000.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pure Bioscience source filings ↗